BMO Capital Markets Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its target price increased by equities researchers at BMO Capital Markets from $135.00 to $150.00 in a research report issued on Monday, Marketbeat reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price suggests a potential upside of 6.41% from the company’s previous close.

A number of other research analysts also recently weighed in on GILD. Rothschild & Co Redburn upped their price objective on shares of Gilead Sciences from $153.00 to $159.00 and gave the stock a “buy” rating in a research report on Tuesday, January 20th. HSBC boosted their price objective on Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research note on Wednesday, December 10th. Daiwa Capital Markets raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research report on Thursday, November 13th. Argus lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, JPMorgan Chase & Co. raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $135.36.

Gilead Sciences Stock Performance

Shares of GILD opened at $140.97 on Monday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The firm has a market cap of $174.90 billion, a PE ratio of 21.86, a P/E/G ratio of 0.72 and a beta of 0.33. The stock has a fifty day moving average price of $124.53 and a 200-day moving average price of $119.10. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $141.71.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kelly A. Kramer sold 2,805 shares of the firm’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director owned 1,339 shares in the company, valued at $170,186.90. The trade was a 67.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 247,397 shares of company stock worth $31,986,612 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. GoalVest Advisory LLC grew its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the third quarter valued at about $26,000. Financial Consulate Inc. increased its position in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 109 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences in the second quarter worth about $27,000. Finally, BOCHK Asset Management Ltd purchased a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple major banks raised price targets and kept bullish ratings, increasing investor conviction that upside remains (Citigroup to $156, UBS to $155, BMO to $150, Truist to $145). Analysts cited in these notes are maintaining buy/outperform views, which supports demand for GILD. Citigroup price‑target note UBS/Truist coverage BMO note
• Positive Sentiment: Press reports note GILD reached a new 1‑year high on the analyst upgrade momentum — a technical trigger that can attract momentum buyers and ETFs. AmericanBankingNews article
• Neutral Sentiment: Company fundamentals and guidance remain supportive: Gilead’s most recent quarter beat EPS and revenue expectations and management set FY2025 EPS guidance (8.05–8.25), which underpins analyst optimism but is not new today. (See analyst consensus and company metrics for context.) MarketBeat company summary
• Negative Sentiment: GILD’s CEO, Daniel Patrick O’Day, sold 115,640 shares (avg $135) in a disclosed transaction — a large insider sale that may prompt concern or profit‑taking among some investors despite his remaining sizeable stake. The SEC filing and trade detail are public. SEC Form 4 (insider sale) InsiderTrades report

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.